Humacyte Statistics

Total Valuation

Humacyte has a market cap or net worth of $608.52 million. The enterprise value is $569.54 million.

Market Cap	608.52M
Enterprise Value	569.54M

Important Dates

The next estimated earnings date is Monday, August 12, 2024, before market open.

Earnings Date	Aug 12, 2024
Ex-Dividend Date	n/a

Share Statistics

Humacyte has 119.08 million shares outstanding. The number of shares has increased by 4.83% in one year.

Shares Outstanding	119.08M
Shares Change (YoY)	+4.83%
Shares Change (QoQ)	+4.47%
Owned by Insiders (%)	30.67%
Owned by Institutions (%)	19.84%
Float	83.19M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	23.27
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.37, with a Debt / Equity ratio of 2.93.

Current Ratio	8.37
Quick Ratio	n/a
Debt / Equity	2.93
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-14.74

Financial Efficiency

Return on equity (ROE) is -306.80% and return on invested capital (ROIC) is -101.40%.

Return on Equity (ROE)	-306.80%
Return on Assets (ROA)	-69.60%
Return on Capital (ROIC)	-101.40%
Revenue Per Employee	n/a
Profits Per Employee	-$577,612
Employee Count	183
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +79.93% in the last 52 weeks. The beta is 1.61, so Humacyte's price volatility has been higher than the market average.

Beta (5Y)	1.61
52-Week Price Change	+79.93%
50-Day Moving Average	5.84
200-Day Moving Average	3.69
Relative Strength Index (RSI)	41.07
Average Volume (20 Days)	3,278,906

Short Selling Information

The latest short interest is 5.20 million, so 4.37% of the outstanding shares have been sold short.

Short Interest	5.20M
Short Previous Month	4.91M
Short % of Shares Out	4.37%
Short % of Float	6.26%
Short Ratio (days to cover)	1.65

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-104.11M
Pretax Income	-105.70M
Net Income	-105.70M
EBITDA	-91.50M
EBIT	-98.99M
Earnings Per Share (EPS)	-$1.00

Full Income Statement

Balance Sheet

The company has $115.51 million in cash and $76.53 million in debt, giving a net cash position of $38.98 million or $0.33 per share.

Cash & Cash Equivalents	115.51M
Total Debt	76.53M
Net Cash	38.98M
Net Cash Per Share	$0.33
Equity (Book Value)	26.15M
Book Value Per Share	0.22
Working Capital	103.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$82.01 million and capital expenditures -$1.52 million, giving a free cash flow of -$83.53 million.

Operating Cash Flow	-82.01M
Capital Expenditures	-1.52M
Free Cash Flow	-83.53M
FCF Per Share	-$0.77

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Humacyte does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.83%
Shareholder Yield	-4.83%
Earnings Yield	-17.37%
FCF Yield	-13.73%

Analyst Forecast

The average price target for Humacyte is $7.00, which is 36.99% higher than the current price. The consensus rating is "Buy".

Price Target	$7.00
Price Target Difference	36.99%
Analyst Consensus	Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2